enVista Envy full range of vision intraocular lens (IOL) met all primary efficacy and safety endpoints in multicenter study Results show that enVista Envy IOLs deliver excellent visual performance, good contrast sensitivity and a favorable dysphotopsia profile VAUGHAN, Ontario / Sep 11, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see... Read More

XIIDRA significantly improved end-of-day eye dryness and discomfort and delivered longer comfortable contact lens wear time in as little as two weeks Continued use further improved discomfort VAUGHAN, Ontario / Sep 09, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophthalmology has... Read More

ASANA offers a comprehensive, customizable gas permeable portfolio including spherical, aspheric, toric, multifocal, reverse geometry and keratoconic lenses Designed for durability, ASANA lenses maintain shape throughout the day, resist protein buildup, and provide enhanced visual acuity, particularly for patients with complex vision challenges such as astigmatism, keratoconus and post-surgical conditions Eye care... Read More

VAUGHAN, Ontario / Aug 18, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the Amended and Restated Director Appointment and Nomination Agreement, dated as of June 21, 2022, by and among the company and Mr. Carl C. Icahn and certain of his affiliates, terminated pursuant to its terms when the... Read More

VAUGHAN, Ontario / Aug 14, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that members of its management team will participate in two investor conferences in September: J.P. Morgan European Leveraged Finance Conference September 3, 2025, London, U.K. Morgan Stanley Global Healthcare Conference... Read More

Revenue of $1.278 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $62 Million Adjusted EBITDA (non-GAAP) 1 of $191 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP) 1 of $192 Million Revenue Grew 5% as Reported and 3% on a Constant Currency 1 Basis Compared to the Second Quarter of 2024, which Absorbs the enVista ® Intraocular Lenses Voluntary Recall Raising Full-Year 2025 Guidance to Reflect... Read More

Phase 3 data show Bausch + Lomb’s LUMIFY Preservative Free eye drops are as safe and effective as the original LUMIFY in reducing ocular redness The multicenter study with 380 participants confirmed that LUMIFY Preservative Free eye drops are non-inferior in efficacy to the original LUMIFY and have a favorable safety profile, offering an effective preservative-free option for sensitive eyes LUMIFY delivers noticeable results... Read More

New survey data reinforces the importance of ongoing awareness and education to help dry eye sufferers seek relief sooner Eyes Tell the Story campaign aims to close the awareness gap through personal stories and portraits of those living with dry eye Additional information and dry eye resources available at KnowYourDryEye.com, including opportunity to share your own dry eye story VAUGHAN, Ontario / Jul 01, 2025 / Business... Read More

VAUGHAN, Ontario / Jun 30, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 30, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on... Read More

VAUGHAN, Ontario / Jun 26, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the “Issuers”), have closed the upsized offering of €675 million aggregate principal amount of... Read More

VAUGHAN, Ontario / Jun 18, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the “Issuers”), have priced the offering of €675 million aggregate principal amount of senior... Read More

VAUGHAN, Ontario / Jun 10, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the “Issuers”), have launched an offering of €600 million aggregate principal amount of senior... Read More

Blink Nourish and Blink Boost are now available at most U.S. national retailers, including Walmart, Target, CVS, Walgreens and Amazon Blink Nourish is the first and only vitamin-enriched preservative-free eye drop designed to replenish and rebalance the tear film Blink Boost’s formula is pH-balanced to match healthy tears, making it comfortable when applied VAUGHAN, Ontario / Jun 04, 2025 / Business Wire / Bausch + Lomb... Read More

VAUGHAN, Ontario / May 22, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chief Financial Officer Sam Eldessouky is scheduled to participate in the 2025 Jefferies Global Healthcare Conference in New York City on June 4, 2025, at 7:35 a.m. ET. A live webcast of the conference will be available on... Read More

VAUGHAN, Ontario / May 21, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the “Annual Meeting”) held on May 21, 2025. Detailed results of the vote follow: Name For Against Broker... Read More

VAUGHAN, Ontario / May 21, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of LUMIFY Preservative Free redness reliever eye drops, the first and only preservative-free over-the-counter eye drops with low-dose brimonidine tartrate 0.025% that relieve redness of the eye due to minor eye... Read More

VAUGHAN, Ontario / May 14, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Zenlens CHROMA HOA scleral contact lenses. Designed to correct advanced higher-order aberrations (HOA), this custom, wavefront-guided scleral lens technology delivers enhanced vision and improves clarity by... Read More

VAUGHAN, Ontario / May 07, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced CE Mark approval for the LuxLife full range of vision intraocular lens (IOL). The preloaded IOL provides patients with natural, continuous vision, from distance to near. Today’s announcement reinforces Bausch + Lomb’s... Read More

Revenue of $1.137 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $212 Million Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP) 1 of $126 Million Revenue Grew 3% as Reported and 5% on a Constant Currency 1 Basis Compared to the First Quarter of 2024 Updating Full-Year 2025 Guidance to Reflect Estimated One-Time Impact of enVista® Intraocular Lenses Voluntary Recall and Impact of Foreign Exchange... Read More

VAUGHAN, Ontario / Apr 24, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has identified the event that led to its recent voluntary recall of intraocular lenses (IOLs) on the enVista platform. Now that the cause and affected lots have been confirmed, the company will return these models to market.... Read More

VAUGHAN, Ontario / Apr 21, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collected a total of 103,169,500 units, or 625,026 pounds, of used contact lenses, eye care and lens care materials in the United States. That’s... Read More

VAUGHAN, Ontario / Mar 27, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary recall of intraocular lenses (IOLs) on its enVista platform. This action was taken out of an abundance of caution after the company received reports of complications, the cause of which could not immediately be... Read More

VAUGHAN, Ontario / Mar 26, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available... Read More

VAUGHAN, Ontario / Mar 17, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Arise, a lens fitting system that uses intelligent, cloud-based technology to streamline the orthokeratology lens design process. Arise seamlessly syncs directly with topographers – diagnostic tools that... Read More

Fourth-Quarter 2024 Financial Results Revenue of $1.280 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $3 Million Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) 1 of $259 Million Revenue Grew 9% as Reported and 11% on a Constant Currency 1 Basis Compared to the Fourth Quarter of 2023, with Growth Across All Segments Full-Year 2024 Financial Results Revenue of $4.791 Billion GAAP Net Loss Attributable... Read More

VAUGHAN, Ontario / Feb 06, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following update on a potential sale, which was disclosed in December 2024 following a regulatory request: “Taking Bausch + Lomb private with a third-party buyer was one of several options being explored to complete a full... Read More

VAUGHAN, Ontario / Jan 22, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 19, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials... Read More

VAUGHAN, Ontario / Jan 13, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Whitecap Biosciences, LLC, which is currently developing two innovative therapies for potential use in glaucoma and geographic atrophy (GA). The acquisition strengthens Bausch + Lomb’s expanding... Read More

VAUGHAN, Ontario / Jan 13, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union after receiving a CE Mark late last year. enVista Aspire combines novel Intermediate Optimized optics, which are... Read More

VAUGHAN, Ontario / Jan 02, 2025 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, M.D., will participate in a company presentation at the 43 rd Annual J.P.... Read More

VAUGHAN, Ontario / Dec 12, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO): “The Bausch + Lomb Board of Directors authorized management and its advisors to explore a potential sale, which is one of... Read More

VAUGHAN, Ontario / Dec 11, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affiliate has acquired Elios Vision, Inc. , developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. The acquisition unlocks new... Read More

VAUGHAN, Ontario / Nov 14, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collected a total of 94,119,275 units*, or 569,743 pounds, of used contact lenses, eye care and lens care materials in the United States. That’s... Read More

Revenue of $1.196 Billion GAAP Net Income Attributable to Bausch + Lomb Corporation of $4 Million Adjusted EBITDA (non-GAAP) 1 of $212 Million; Adjusted EBITDA excluding Acquired IPR&D (non-GAAP) 1 of $227 Million Revenue Grew 19% as Reported and 19% on a Constant Currency 1 Basis Compared to the Third Quarter of 2023, Driven by Solid Execution and Growth Across All Segments Raising Full-Year 2024 Revenue Guidance VAUGHAN,... Read More

VAUGHAN, Ontario / Oct 14, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has approved the enVista ® Envy™ full range of vision intraocular lens (IOL), which offers a continuous range of vision with excellent dysphotopsia tolerance on the widely used enVista... Read More

VAUGHAN, Ontario / Oct 09, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made... Read More

VAUGHAN, Ontario / Oct 01, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce marketplace. Designed to help maximize efficiencies for eye care practices while enhancing the patient experience, Opal provides a streamlined ordering process for Bausch + Lomb... Read More

Revenue of $1.216 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $151 Million Adjusted EBITDA (non-GAAP ) 1 of $209 Million Revenue Grew 17% as Reported and 20% on a Constant Currency 1 Basis Compared to the Second Quarter of 2023, Driven by Broad-Based Growth Across All Business Segments Raising Full-Year 2024 Revenue and Adjusted EBITDA (non-GAAP) 1 Guidance VAUGHAN, Ontario / Jul 31, 2024 / Business... Read More

VAUGHAN, Ontario / Jul 11, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2024 financial results on Wednesday, July 31, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made... Read More

New Online Resource, KnowYourDryEye.com, Aims to Increase Awareness and Education VAUGHAN, Ontario / Jul 08, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today shared results from the company’s inaugural State of Dry Eye survey, which explores dry eye understanding and experiences among American adults. Dry eye is... Read More

Events Include Symposium on Patient-Centric Approaches to Dry Eye, Highlighting Breakthroughs in Diagnosis, Treatment and Care VAUGHAN, Ontario / Jun 17, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of several scientific presentations and educational events during the European Dry... Read More

VAUGHAN, Ontario / Jun 10, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily disposable contact lenses. Engineered with a next-generation lens material infused with ProBalance Technology™ and the company’s proprietary OpticAlign ®... Read More

VAUGHAN, Ontario / Jun 03, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink NutriTears, a clinically proven over-the-counter supplement that targets the key root causes of dry eyes, promotes healthy tear production and provides noticeable relief of eye dryness symptoms in as... Read More

VAUGHAN, Ontario / May 29, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2024 annual meeting of shareholders (the “Annual Meeting”) held on May 29, 2024. The detailed results of the vote for the election of... Read More

15 ePosters and In-Person Presentations Will Include Clinical Data on Blink™ NutriTears ® Supplement for Dry Eyes, Blink® Triple Care Lubricating Eye Drops and MIEBO ® (Perfluorohexyloctane Ophthalmic Solution) VAUGHAN, Ontario / May 28, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation... Read More

VAUGHAN, Ontario / May 28, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista ® Envy™* full visual range intraocular lens (IOL). This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia... Read More

Revenue of $1.099 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $167 Million Adjusted EBITDA (non-GAAP) 1 of $180 Million Revenue Grew 18% as Reported and 20% on a Constant Currency 1 Basis Compared to the First Quarter of 2023, Driven by Growth Across All Business Segments Foreign Exchange Negatively Impacted Revenue by Approximately $20 Million Raising Full-Year 2024 Constant Currency Revenue Growth 1... Read More

21 Poster Presentations include Evaluations of Consumer, Pharmaceutical, Surgical and Vision Care Products and Pipeline Programs, Including a Novel Dry Eye Nutritional Supplement VAUGHAN, Ontario / Apr 29, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 scientific poster... Read More

Novel Supplement Shown to Address Signs and Symptoms of Dry Eyes, All Primary Endpoints Achieved VAUGHAN, Ontario / Apr 25, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Frontiers in Ophthalmology published statistically significant results from a clinical study evaluating the efficacy and safety of... Read More

VAUGHAN, Ontario / Apr 18, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ONE by ONE and Biotrue ® Eye Care Recycling programs have collected 84,343,540 units, or 510,116 pounds, of used contact lenses, eye care and lens care materials in the U.S., which is greater than the weight of the Statue... Read More

VAUGHAN, Ontario / Apr 15, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available... Read More

Presentations Will Feature Studies Evaluating TENEO ™ Excimer Laser Platform, MIEBO ® (Perfluorohexyloctane Ophthalmic Solution) and enVista ® Envy* and IC-8 ® Apthera ™ IOLs VAUGHAN, Ontario / Mar 27, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced fifteen podium and four poster presentations during... Read More

Richard De Schutter to Retire from Board Following 2024 Annual Meeting VAUGHAN, Ontario / Feb 28, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the “Board”), effective immediately. Current director Richard De Schutter will retire from... Read More

Fourth-Quarter 2023 Financial Results Revenue of $1.173 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $54 Million Adjusted EBITDA (non-GAAP) 1 of $231 Million Revenue Grew 18% as Reported and 19% on a Constant Currency 1 Basis Compared to the Fourth Quarter of 2022, Driven by Growth Across All Segments Full-Year 2023 Financial Results Revenue of $4.146 Billion GAAP Net Loss Attributable to Bausch + Lomb... Read More

VAUGHAN, Ontario / Feb 05, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2023 financial results on Wednesday, Feb. 21, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will... Read More

First Excimer Platform Approved in Nearly Two Decades Offers Accuracy, Efficiency and Usability Advantages VAUGHAN, Ontario / Jan 08, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ... Read More

VAUGHAN, Ontario / Jan 03, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat with investors at the 42 nd Annual J.P. Morgan Healthcare Conference on Jan. 8, 2024, at 11:15 a.m. PT (2:15 p.m. ET). Other company executives, including... Read More

VAUGHAN, Ontario / Nov 15, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE and Biotrue Eye Care Recycling programs have collected a total of 76,645,000 million units, or 464,100 pounds, of used contact lenses, eye care and lens care materials in the United States, which is... Read More

Revenues of $1.007 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $84 Million Adjusted EBITDA (non-GAAP) 1 of $187 Million Revenues Grew 7% as Reported and 8% on a Constant Currency 1 Basis Compared to the Third Quarter of 2022, Driven by Growth in the Vision Care and Surgical Segments Foreign Exchange Negatively Impacted Revenues and Adjusted EBITDA (non-GAAP) 1 by Approximately $10 Million and $14... Read More

Presentations Will Feature Studies Evaluating MIEBO™ (Perfluorohexyloctane Ophthalmic Solution), IC-8 ® Apthera™ IOL and ARMOR Surveillance Study Data Company Will Host Six Educational Events VAUGHAN, Ontario / Oct 26, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced three podium presentations and... Read More

VAUGHAN, Ontario / Oct 16, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2023 financial results on Wednesday, Nov. 1, 2023. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made... Read More

Presentations Will Feature Blink ® Triple Care Lubricating Dry Eye Drops, MIEBO™ (perfluorohexyloctane ophthalmic solution) and Bausch + Lomb INFUSE ® Multifocal Lenses Company Will Host Seven Educational Events VAUGHAN, Ontario / Oct 04, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced one podium... Read More

Poised for Significant Growth in Prescription Dry Eye Segment VAUGHAN, Ontario / Sep 29, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has completed its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry... Read More

First of its Kind Specialty Eye Care Products Clinically Proven to Support Beautiful, Healthy-Looking Eyes VAUGHAN, Ontario / Sep 26, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of LUMIFY EYE ILLUMINATIONS , a new line of hypoallergenic specialty eye care products scientifically... Read More

VAUGHAN, Ontario / Sep 20, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ONE by ONE and Biotrue Eye Care Recycling programs have been recognized as 2023 Sustainability Award winners by Business Intelligence Group in the “Sustainability Service of the Year” category. “Millions of people wear... Read More

VAUGHAN, Ontario / Sep 14, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Bausch + Lomb Escrow Corp. (“Escrow Issuer”), a wholly owned subsidiary of the company, has priced its previously announced offering of $1.4 billion aggregate principal amount of 8.375% senior secured notes due 2028... Read More

MIEBO is the First and Only Prescription Eye Drop that Directly Targets Tear Evaporation, the Leading Cause of Dry Eye Disease VAUGHAN, Ontario / Sep 12, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. commercial launch of MIEBO (perfluorohexyloctane ophthalmic solution) for the treatment of... Read More

LAVAL, QC / ACCESSWIRE / September 11, 2023 / Bausch + Lomb Corporation ("Bausch + Lomb") (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (the "Company") (NYSE/TSX:BHC), announced today that, in connection with the financing of its pending acquisition (the "Acquisition") of XIIDRA® and certain other ophthalmology assets, Bausch + Lomb Escrow Corp. (the "Escrow Issuer"), a wholly owned subsidiary of Bausch +... Read More

VAUGHAN, Ontario / Sep 11, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Bausch + Lomb Escrow Corp. (“Escrow Issuer”), a wholly owned subsidiary of the company, has launched an offering of $1.4 billion aggregate principal amount of new senior secured notes due 2028 (“Notes”) and that the... Read More

VAUGHAN, Ontario / Sep 06, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it has disclosed certain historical and pro forma financial information with respect to its proposed acquisition of XIIDRA (lifitegrast ophthalmic solution) 5% and certain other ophthalmology assets (“Acquisition”) on a... Read More

Company-Sponsored Educational Events Will Feature Latest Surgical Technologies, Including the SeeLuma™ Fully Digital Surgical Visualization Platform, MIMS ® and the IC-8 ® Apthera IOL VAUGHAN, Ontario / Sep 06, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced 13 podium and poster presentations during... Read More

VAUGHAN, Ontario / Aug 29, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders is scheduled to participate at the 2023 Wells Fargo Healthcare Conference in Boston on Sept. 6, 2023, at 10:15 a.m. ET. A live webcast and audio archive of the conference will be available... Read More

VAUGHAN, Ontario / Aug 24, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (the “HSR Act”), with respect to the previously announced agreement to acquire XIIDRA (lifitegrast ophthalmic solution)... Read More

Revenues of $1.035 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $32 Million Adjusted EBITDA (non-GAAP) 1 of $179 Million Revenues Grew 10% as Reported and 12% on a Constant Currency 1 Basis Compared to the Second Quarter of 2022, Driven by Growth Across All Segments Foreign Exchange Negatively Impacted Revenues and Adjusted EBITDA (non-GAAP) 1 by Approximately $18 Million and $25 Million, Respectively... Read More

VAUGHAN, Ontario / Aug 01, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its executive leadership team including the creation of two new roles. The moves build on a reshuffling announced in early June after Chairman and CEO Brent Saunders, who previously served as CEO from 2010 to 2013,... Read More

VAUGHAN, Ontario / Jul 11, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2023 financial results on Wednesday, Aug. 2, 2023. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made... Read More

VAUGHAN, Ontario / Jul 06, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has purchased the Blink ® product line of eye and contact lens drops from Johnson & Johnson Vision.* The strategic acquisition is the latest example of the company’s commitment to increasing over-the-counter (OTC)... Read More

Acquisition Represents Significant Opportunity for Growth in Prescription Dry Eye Segment VAUGHAN, Ontario / Jun 30, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has entered into a definitive agreement with Novartis under which Bausch + Lomb will acquire XIIDRA ® (lifitegrast ophthalmic... Read More

Only Eye Vitamin That Supports Two Health Benefits in One, Clinically Proven AREDS 2 Formula for Eye Health and 100 mg of CoQ10 Antioxidant for Heart Health* VAUGHAN, Ontario / Jun 12, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of PreserVision ® AREDS 2 Formula... Read More

A Total of 11 Poster Presentations Will Be Presented, Including Data from Two Pivotal Phase 3 Trials and 12-Month Safety Extension Trial of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) VAUGHAN, Ontario / Jun 08, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced that researchers... Read More

First and Only Preservative-Free Contact Lens Rehydrating Drop in a Multi-Dose Bottle Provides Up to Eight Hours of Moisture* For Dry Contact Lenses Now Available at Most Major U.S. Retailers VAUGHAN, Ontario / Jun 06, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch... Read More

New Multifocal Daily Disposable Lens Provides Clear Vision at All Distances, All-Day Comfort and Helps Minimize Contact Lens Dryness VAUGHAN, Ontario / Jun 05, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Bausch + Lomb INFUSE ® Multifocal silicone hydrogel... Read More

VAUGHAN, Ontario / Jun 01, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced a reshaping of its executive leadership team, including the elevation of all business unit heads. Luc Bonnefoy, senior vice president (SVP), Surgical; John Ferris, SVP, Consumer; and Yang Yang, SVP,... Read More

MIEBO is the First and Only Prescription Eye Drop Approved for Dry Eye Disease that Directly Targets Tear Evaporation, Based on Consistent Results from Two Consecutive Pivotal Phase 3 Trials VAUGHAN, Ontario & HEIDELBERG, Germany / May 18, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Novaliq... Read More

Revenues of $931 Million GAAP Net Loss Attributable to Bausch + Lomb Corporation of $90 Million Adjusted EBITDA (non-GAAP) 1 of $141 Million Revenues Grew 5% as Reported and 8% on a Constant Currency 1 Basis Compared to the First Quarter of 2022, Driven by Growth Across All Segments Foreign Exchange Negatively Impacted Revenues and Adjusted EBITDA (non-GAAP) 1 by $31 Million and $14 Million, Respectively VAUGHAN, Ontario /... Read More

Report Highlights Progress and Priorities Across ESG Initiatives Around the World VAUGHAN, Ontario / May 01, 2023 / Business Wire / Bausch + Lomb Corporation , (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today released its annual Environmental, Social and Governance (ESG) Report , highlighting the Company’s... Read More

Company-Sponsored Educational Events will Focus on Dry Eye Disease and IC-8 ® Apthera™ Intraocular Lens VAUGHAN, Ontario / Apr 26, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 podium presentations and four poster presentations related to the company’s... Read More

VAUGHAN, Ontario / Apr 25, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2023 annual meeting of shareholders (the “Annual Meeting”) held on April 24, 2023. The detailed results of the vote for the election of... Read More

Two New OVDs Offer Surgeons Dual-Action Protection during Cataract Surgery VAUGHAN, Ontario / Apr 24, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of StableVisc™ cohesive ophthalmic viscosurgical device (OVD) as well as TotalVisc™ Viscoelastic System. StableVisc... Read More

Eight Poster Presentations Include Results from 12-Month Safety Extension Trial of Investigational Treatment NOV03 (Perfluorohexyloctane), as well as Data on XIPERE ® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use VAUGHAN, Ontario / Apr 20, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to... Read More

VAUGHAN, Ontario / Apr 18, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE and Biotrue ® Eye Care Recycling programs have recycled a total of 65.8 million units, or 397,194 pounds, of used contact lenses, eye care and lens care materials, which is equivalent... Read More

VAUGHAN, Ontario / Apr 17, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2023 financial results on Wednesday, May 3, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update. All materials... Read More

New Technology Provides Cutting Edge Visualization, Ergonomic Positioning and Efficient Workflow VAUGHAN, Ontario & HEIDELBERG, Germany / Apr 13, 2023 / Business Wire / Bausch + Lomb , a leading global eye health company dedicated to helping people see better to live better, and Heidelberg Engineering, today announced the introduction of the SeeLuma ™ Fully Digital Surgical Visualization Platform, which provides ophthalmic... Read More

Mr. Bailey and Mr. Stewart Will Join Bausch + Lomb on April 24, 2023 VAUGHAN, Ontario / Apr 12, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president,... Read More

NOV03 Consistently Met Primary Endpoints for Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction NOV03 PDUFA Action Date is June 28, 2023 VAUGHAN, Ontario & HEIDELBERG, Germany / Mar 22, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a... Read More

VAUGHAN, Ontario / Feb 22, 2023 / Business Wire / Bausch + Lomb Corporation , (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2022 financial results. “Bausch + Lomb delivered another year of strong performance in 2022, growing the business organically 1,2 at a... Read More

VAUGHAN, Ontario / Feb 15, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer (“CEO”) and chair of the Board of Directors (“Board”) of the Company, effective March 6, 2023. Concurrent with this appointment, and as... Read More

VAUGHAN, Ontario / Jan 23, 2023 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2022 financial results on Wednesday, Feb. 22, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business... Read More

Acquisition Will Enhance Bausch + Lomb’s Surgical Portfolio with IC-8 ® Apthera ™ Intraocular Lens Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. (“AcuFocus”), a privately held ophthalmic medical device company, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a... Read More

Enhanced Vitamin Includes the Same Clinically Proven AREDS 2 Formula with New Lutein and Zeaxanthin Formulation that Offers Superior Absorption Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S.... Read More

Bausch + Lomb Corporation , (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, has published a company update presentation designed to complement remarks that will be provided by management at 3:00 p.m. PT (6:00 p.m. ET) today, Jan. 9, 2023, during the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation... Read More

Bausch + Lomb Corporation , (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced that Joseph C. Papa, chief executive officer, and Sam Eldessouky, executive vice president and chief financial officer, are scheduled to participate at the 41 st Annual J.P. Morgan Healthcare Conference on Jan. 9, 2023, at 3:00 p.m. PT (6:00 p.m. ET). A... Read More

NOV03 is Being Investigated to Treat the Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction NOV03 PDUFA Action Date is June 28, 2023 Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in class ocular therapeutics, today... Read More

New Educational Campaign Aims to Educate Individuals Who May be at Risk for Glaucoma and Raise Funding for Glaucoma Research Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national non-profit organization with the vision of curing glaucoma, today announced the U.S. launch of ‘... Read More

VAUGHAN, ON , Dec. 22, 2022 /CNW/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced that the Company and its CEO, Joseph C. Papa , have entered into an Amended and Restated Separation Agreement (the "Amended Separation Agreement"), pursuant to which Mr. Papa has agreed to continue serving... Read More

Provides Lenses Up to Eight Hours of Moisture* VAUGHAN, ON , Dec. 13, 2022 /CNW/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Biotrue Hydration Boost Contact Lens Rehydrating drops, a preservative-free... Read More

VAUGHAN, ON , Dec. 12, 2022 /CNW/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced its first-of-its-kind ONE by ONE and Biotrue Eye Care Recycling programs have been named a gold winner in the Most Environmentally Friendly Service of the Year category by the 2022 Best in Biz Awards. "For the past two... Read More

VAUGHAN, ON , Nov. 29, 2022 /CNW/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced its latest contact lens solution, Biotrue Hydration Plus, has received Business Intelligence Group's (BIG) 2022 BIG Awards for Business Product of the Year award. "Biotrue Hydration Plus was built upon our successful... Read More